NeoPhore lures former Kite exec to be its CEO
UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael Shih as chief executive (CEO) and to the board of directors, effective immediately.
Mr Shih has nearly 20 years of experience in business development, licensing and mergers and acquisitions. He was most recently vice president of corporate development at Kite Pharma, part of Gilead Sciences (Nasdaq: GILD), where he led multiple business development opportunities for the company.
Before this, Mr Shih was senior vice president, head of business development at Biogen (Nasdaq: BIIB), leading the team responsible for sourcing, structuring and executing strategic collaborations and merger and acquisition opportunities. Prior to joining Biogen, he was VP and head of global transactions at Sanofi (Euronext: SAN), where he oversaw the structuring and negotiation of business development transactions across Sanofi’s business units. He has also held senior business development roles at Epizyme, Forest Laboratories and Eisai.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze